ALXO Alx Oncology Holdings Inc
Price (delayed)
$2.21
Market cap
$116.4M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.63
Enterprise value
$110.64M
ALX Oncology Holdings Inc. operates as a clinical stage immuno-oncology company. The Company focuses on helping patients fight cancer by developing therapies that bridge the innate and adaptive immune system.
Highlights
The EPS is down by 13% year-on-year but it is up by 2.2% since the previous quarter
The quick ratio has dropped by 66% year-on-year and by 17% since the previous quarter
ALXO's net income is down by 32% year-on-year and by 3.2% since the previous quarter
Key stats
What are the main financial stats of ALXO
Market
Valuations
Earnings
Shares outstanding
52.67M
Market cap
$116.4M
Enterprise value
$110.64M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.72
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$169.78M
EBITDA
-$168.93M
Free cash flow
-$134.41M
Per share
Balance sheet
Liquidity
EPS
-$3.63
Free cash flow per share
-$2.59
Book value per share
$3.06
Revenue per share
$0
TBVPS
$4.14
Total assets
$214.62M
Total liabilities
$55.3M
Debt
$9.77M
Equity
$159.32M
Working capital
$130.26M
Debt to equity
0.06
Current ratio
4.39
Quick ratio
4.08
Net debt/EBITDA
0.03
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-77.1%
Return on equity
-100.6%
Return on invested capital
-95%
Return on capital employed
-96.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALXO stock price
How has the Alx Oncology Holdings stock price performed over time
Intraday
1.38%
1 week
1.38%
1 month
-12.99%
1 year
-57.17%
YTD
-85.16%
QTD
-63.35%
Financial performance
How have Alx Oncology Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$180.59M
Net income
-$171.44M
Gross margin
N/A
Net margin
N/A
ALXO's net income is down by 32% year-on-year and by 3.2% since the previous quarter
ALXO's operating income is down by 31% YoY and by 2.7% QoQ
Growth
What is Alx Oncology Holdings's growth rate over time
Valuation
What is Alx Oncology Holdings stock price valuation
P/E
N/A
P/B
0.72
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is down by 13% year-on-year but it is up by 2.2% since the previous quarter
The price to book (P/B) is 79% less than the 5-year quarterly average of 3.4 and 73% less than the last 4 quarters average of 2.6
Alx Oncology Holdings's equity has decreased by 25% YoY and by 3% QoQ
Efficiency
How efficient is Alx Oncology Holdings business performance
ALXO's return on equity has dropped by 93% year-on-year and by 11% since the previous quarter
The return on assets has dropped by 70% year-on-year and by 7% since the previous quarter
ALXO's return on invested capital has dropped by 62% year-on-year and by 7% since the previous quarter
Dividends
What is ALXO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALXO.
Financial health
How did Alx Oncology Holdings financials performed over time
The quick ratio has dropped by 66% year-on-year and by 17% since the previous quarter
The total liabilities has surged by 66% year-on-year and by 14% since the previous quarter
The debt is 94% smaller than the equity
Alx Oncology Holdings's debt to equity has soared by 50% YoY
Alx Oncology Holdings's equity has decreased by 25% YoY and by 3% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.